Skip to content
AASLD Family of Websites: Liver Fellow Network
AASLD.org AASLD Foundation LiverLearning Career Center Journals The Liver Meeting HCV Guidelines
AASLD Logo
AASLD Logo

LFN Main Navigation

  • Topics
  • Core Series
    Back to Basics Clinical Pearls Webinars Evidence Corner Pathology Pearls Liver Talks Podcasts The Why? Series Tools of the Trade View All Core Series
  • Tweetorials
  • About
  • Acute Liver Failure
  • Alcohol-Associated Liver Disease
  • Autoimmune Hepatitis
  • Career Development and Mentorship
  • Cholestatic Liver Disease
  • Complications of Liver Disease and Portal Hypertension
  • Drug-Induced Liver Disease
  • Guidelines
  • HepMadness
  • Inherited Disorders
  • Liver Anatomy, Development, and Physiology
  • Liver Infections
  • Liver Physiology
  • Liver Related Infections
  • MASLD/MASH
  • Neoplasms of the Liver
  • Pathology
  • Pediatrics
  • Practice Questions
  • Pregnancy-Related Liver Disease
  • Symptoms and Clinical Presentation of Liver Disease and Portal HTN
  • Systemic Conditions with Hepatic Manifestations
  • Transplantation and Surgery
  • Vascular
  • Video Tutorials
  • Viral Hepatitis
  • Core Series
  • Evidence Corner
  • Phase 3 Trial Of Resmetirom In MASH With Liver Fibrosis

Phase 3 Trial of Resmetirom in MASH with Liver Fibrosis

July 3, 2024

Richie Manikat

Share

Copy Link Twitter Facebook

https://pubmed.ncbi.nlm.nih.gov/38324483/

Share

Copy Link Twitter Facebook

Written By:

Richie Manikat

Gastroenterology Fellow, Stanford

Related Content

Can POCUS guide volume management in cirrhosis patients with acute kidney injury?

May 18, 2026

Can Efruxifermin Reverse Fibrosis in Compensated MASH Cirrhosis?

April 28, 2026

Pediatric Autoimmune Hepatitis: Is Treatment Withdrawal Possible and Safe?

March 16, 2026

AASLD LFN Logo

Follow Us

Disclaimer & Privacy Policy

© 2026 copyright